Insights

In honour of International Women’s Day 2023, and to acknowledge the achievements of the inspiring women in our network, Dehns has interviewed Hedwig van Driel, Senior Patent Attorney at TomTom International B.V. to highlight her experiences of working in a STEM profession.

Intellectual Property infringement and director’s liability: Lauren Palmer, Legal Assistant at Dehns provides a case analysis of Tangle v One for Fun

In episode two of our special “Women in STEM” podcast series, we interview Rebecca Gardner (Partner) and Rosie Lawrence (Technical Assistant).  Rebecca and Rosie work in the Dehns Biotech team and are based in our Brighton office. With Rebecca starting her career in the mid-90s and Rosie joining the workplace in 2020, this episode delves into their different experiences – during their studies and when entering the workplace – and the effect of increased diversity in STEM.

Implication of EPO decision on prior English court decision: Paul Harris, Head of Litigation at Dehns provides a case analysis of Vodafone Group PLC and ors v IPCom GmbH.

What better time to acknowledge the achievements of the women in our firm than the International day of Women and Girls in Science. In celebration of this day, our Senior Partner, Elizabeth Jones, discusses topics ranging from becoming a patent attorney to the importance of normalising the presence of women in STEM (Science, Technology, Engineering and Mathematics) fields.

In honour of International day of Women and Girls in Science, Dehns has interviewed a series of inspiring role models in our network.
Anne Ulvestad, CEO of Arctic Pharma AS, kindly opened up about her experiences in this industry, from her motivation for pursuing a career in STEM to her experience of barriers to entry.

Can adding the company name to a mark avoid infringement?: Lauren Palmer, Legal Assistant at Dehns  provides a case analysis of Combe International v Dr Wolff

Arrow declaration misses its target: Paul Harris, Head of Litigation at Dehns, considers the extent to which the Patents Court will go in order to provide a “spin-off value” for one party, in the courts of another jurisdiction.

A balance must be struck between the competing interests of generic and innovator companies to ensure the healthcare system works at its best. At the moment, that longstanding balance has been disrupted by the Federal Circuit and the ripples are still being felt in the generics industry, even if the court has tried to take some of the sting out of its earlier actions.

In this episode of The IP Podcast, Senior Associate Daniel Rowe discusses a topic relating to the biotechnology and pharma industries: repurposed drugs and skinny labelling.

Tune in to hear Dan answer:

• What are repurposed drugs and why are they important?
• Can repurposed drugs be patent protected even though the patent covering the original drug may have expired?
• What is a skinny label?

All these questions and more, answered in less than 20 minutes!